DBH rs1611146: What Your Genotype Means
The rs1611146 single-nucleotide polymorphism is a common non-coding variant located within the promoter region of the human DBH gene on chromosome 9. This variant has been repeatedly studied for its association with circulating plasma dopamine beta-hydroxylase enzyme levels and subtle shifts in sympathetic nervous system tone. Evidence suggests it may also influence physiological responses to certain adrenergic or neuroactive drugs, although current clinical evidence remains limited.
What each genotype means
High enzyme activity
This genotype is associated with the highest levels of dopamine beta-hydroxylase enzyme activity in the blood. Because this enzyme converts dopamine to norepinephrine, individuals with this profile may have different baseline levels of these neurotransmitters compared to those with the T allele. Please discuss any concerns regarding medication response or physiological symptoms with your clinician or pharmacist.
This is the most common genotype observed in many populations, though frequencies vary significantly by ancestry.
Intermediate enzyme activity
This genotype is associated with intermediate levels of dopamine beta-hydroxylase enzyme activity. Research indicates that carrying one copy of the T allele results in lower enzyme levels compared to the CC genotype. Please discuss any concerns regarding medication response or physiological symptoms with your clinician or pharmacist.
This heterozygous genotype is frequently observed across diverse global populations.
Low enzyme activity
This genotype is associated with the lowest levels of dopamine beta-hydroxylase enzyme activity in the blood. Lower enzyme activity may influence the conversion of dopamine to norepinephrine, which can affect sympathetic nervous system function. Please discuss any concerns regarding medication response or physiological symptoms with your clinician or pharmacist.
This genotype is less common than the CC or CT genotypes, with the T allele frequency typically ranging between 15% and 25%.
What Is rs1611146 and Where Is It Located?
The single nucleotide polymorphism rs1611146 is a common regulatory change found on chromosome 9 within the 5-prime upstream promoter region of the DBH gene, historically described in research literature as -1021C>T. Because it resides in the non-coding promoter area rather than within a protein-coding exon, the variation does not alter the primary amino acid structure of the enzyme itself. Instead, biological investigations indicate that this nucleotide difference alters transcriptional activity, directly modulating the rate at which the gene is transcribed into messenger RNA. In laboratory assays and epidemiological cohorts, the alternate T allele consistently correlates with reduced gene promoter activity, leading to lower quantities of the functional enzyme circulating in the bloodstream compared to the more common C allele.
Biological Function of the DBH Gene
The DBH gene provides instructions for producing dopamine beta-hydroxylase, an essential copper-containing monooxygenase enzyme predominantly synthesized in neuroendocrine tissues, sympathetic nerves, and the adrenal medulla. Its primary metabolic role is catalyzing the conversion of the neurotransmitter dopamine into norepinephrine, also known as noradrenaline. Norepinephrine is critical for maintaining sympathetic vascular tone, regulating blood pressure, mediating the classic fight-or-flight stress response, and shaping central cognitive and mood pathways. Severe homozygous loss-of-function mutations in this gene cause rare congenital dopamine beta-hydroxylase deficiency, characterized by autonomic failure. In contrast, common regulatory polymorphisms like rs1611146 produce benign, continuous quantitative variations in plasma enzyme levels rather than monogenic disease states.
Research Associations and Strength of Evidence
Decades of biochemical genetics research show a strong, reproducible link between rs1611146 and baseline plasma dopamine beta-hydroxylase activity, with the variant accounting for up to 35 to 50 percent of the biochemical variance in enzyme levels across studied groups. Beyond baseline circulating biochemistry, researchers have explored associations between rs1611146 and complex physiological phenotypes, including blood pressure dynamics, sympathetic reactivity, stress response, and pharmacodynamic responses to adrenergic agents or central nervous system active medications. However, the strength of evidence for clinical outcomes and pharmacogenomic utility is categorized as limited. Findings across psychiatric, cardiovascular, and drug-response studies are frequently mixed, variable by ancestral background, or subject to small sample sizes that require further clinical validation.
Population Frequency and Global Distribution
The rs1611146 polymorphism is broadly distributed across human populations worldwide, demonstrating that it represents normal human genetic variation rather than a rare pathogenic mutation. According to global sequencing repositories and population genetics cohorts, the minor allele frequency generally ranges between 15% and 25% across diverse geographical and ancestral ancestries. The standard C allele remains the predominant reference sequence globally, while the T allele exists as a well-established minor allele. Because of these allele dynamics, heterozygous individuals who carry one copy of the variant allele represent a sizable minority of populations worldwide, whereas homozygous carriers of two T alleles form a smaller subset representing approximately 2% to 6% of tested cohorts.
What This Information Means for You
Discovering your rs1611146 genotype provides educational insight into your individual biochemical makeup and how your body regulates adrenergic enzymes, but it cannot be used to diagnose any disease or clinical disorder. This polymorphism describes a subtle statistical baseline variation in enzyme activity rather than a deterministic medical condition. You should never alter, discontinue, or initiate any prescription medication—including blood pressure treatments, antidepressants, or stimulant therapies—based on commercial genetic test results. If you have questions regarding your vascular health, sympathetic response, or how your body handles specific neuroactive medications, always discuss dosing and clinical decisions directly with a licensed physician or clinical pharmacist.
How common is this variant?
The minor allele frequency for rs1611146 ranges between 15% and 25% across diverse global populations, making the heterozygous genotype common and the homozygous minor genotype present in a smaller subset of individuals worldwide.
Frequently asked questions
Does having the rs1611146 variant mean I have dopamine beta-hydroxylase deficiency?
No. Congenital dopamine beta-hydroxylase deficiency is a very rare, severe genetic condition caused by disruptive mutations that eliminate enzyme function. The rs1611146 variant is a common regulatory change that merely alters the normal baseline quantity of the enzyme in your blood, remaining well within the range of normal health.
Can my rs1611146 genotype tell me which medications to take?
No, commercial test results for this variant cannot determine which medications you should take or avoid. While researchers study its subtle impact on adrenergic and neuroactive drug pathways, clinical evidence remains limited and is not sufficient to guide routine prescribing. Always consult a licensed clinician or pharmacist before modifying any medication regimen.
How does the rs1611146 variant affect dopamine and norepinephrine?
The DBH enzyme converts dopamine into norepinephrine. Individuals with the T allele typically express less DBH enzyme, which statistically correlates with lower circulating enzyme activity, though internal neurotransmitter balance is continuously modulated by many other compensatory systems throughout the body.
Is the TT genotype considered dangerous or harmful?
No, having the TT genotype is not considered dangerous or indicative of disease. Millions of healthy individuals carry this genotype worldwide, and it represents a natural biochemical variation in human enzyme expression rather than a clinical pathology.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1611146?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29